Details of the Drug-Related molecule(s) Expression Atlas

General Information of Drug (ID: DMQI970)

Drug Name
Lumoxiti Drug Info
Synonyms Moxetumumab pasudotox-tdfk
Indication
Disease Entry ICD 11 Status REF
Hairy cell leukaemia 2A82.2 Phase 1 [1]
Cross-matching ID
TTD Drug ID
DMQI970

Molecule(s) Related to This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
B-cell receptor CD22 (CD22) TTM6QSK CD22_HUMAN Inhibitor [2]

The Expression Level of Molecule(s) between Disease Section and Healthy Individual Tissue

The Studied Disease Hairy cell leukaemia
ICD Disease Classification 2A82.2
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
B-cell receptor CD22 (CD22) DTT CD22 1.89E-11 -0.21 -0.58
Molecular Expression Atlas between Disease Section and Healthy Individual Tissue

References

1 ClinicalTrials.gov (NCT03805932) Title: Moxetumomab Pasudotox-tdfk (Lumoxiti ) and Rituximab (Rituxan ) for Relapsed Hairy Cell Leukemia. U.S. National Institutes of Health.
2 Clinical pipeline report, company report or official report of Innate Pharma.